PICI Network Researchers to Present at ESMO Congress 2022 #ESMO22

Parker Institute for Cancer Immunotherapy (PICI) Network investigators will be among other leading researchers presenting the latest advances in cancer treatment at ESMO Congress 2022, Sept. 9-13 in Paris and online.

Hosted by the European Society for Medical Oncology, the conference includes presentations by six PICI Network members from four PICI-affiliated institutions:

• Eileen O’Reilly, MD; Geoffrey Y. Ku, MD; and Claire F. Friedman, MD, all of Memorial Sloan Kettering Cancer Center
• Adil Daud, MD, of the University of California, San Francisco
• Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center
• Elizabeth Mittendorf, MD, PhD, of Dana-Farber Cancer Institute

Below are the sessions featuring PICI investigators. Please note that all events listed are subject to change. For the most current information, visit the ESMO Congress program. Follow the meeting live on Twitter using the hashtag #ESMO22.

Sept. 9

Special Symposium: Lessons Learned and New Horizons and Other Hepatobiliary/Pancreatic Malignancies
10:15-11:45 a.m. Central European Summer Time (CEST)

Speaker: Eileen O’Reilly, MD (Twitter: @EileenMOReilly)
Topic: The Role of KRAS Inhibitor and Other New Treatment Options in Pancreatic Cancer
11:05-11:20 a.m. CEST

Special Symposium: How the Tumor Microenvironment Affects Outcome and Therapy Response
Chair and Speaker: Adil Daud, MD (Twitter: @ad1600)
2-3:30 p.m. CEST

• • Topic: Organ-specific Tumor Microenvironment, 2:10-2:25 p.m. CEST
  • Conclusions and Perspectives, 2:55-3 p.m. CEST

Sept. 10

Special Symposium: Progress in the Identification of New Immune Targets
8:30-10 a.m. CEST

Speaker: Padmanee Sharma, MD, PhD (Twitter: @PamSharmaMDPhD)
Topic: Novel Immune Checkpoints, 8:40-8:55 a.m. CEST

Mini Oral Session: GI, Upper Digestive
2:45-4:15 p.m. CEST

Speaker: Geoffrey Y. Ku, MD
Topic: Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
Presentation Number: 1205MO
3:45-3:50 p.m. CEST

Sept. 11

Proffered Paper Session: Basic Science & Translational Research
4:30-6 p.m. CEST

Speaker: Claire F. Friedman, MD (Twitter: @ClaireFriedma19)
Topic: MyPathway: A Multiple Target, Multiple Basket Study of Targeted Treatments in Tissue-agnostic Cohorts of Patients with Advanced Solid Tumors
Presentation Number: 66O
4:50-5 p.m. CEST

Sept. 12

Multidisciplinary Session: Oligometastatic Disease and Oligoprogression in Breast Cancer
3-4 p.m. CEST

Speaker: Elizabeth Mittendorf, MD, PhD (Twitter: @EMittendorfMD)
Topic: Surgery
3:20-3:35 p.m. CEST